M. Kelly

发表

Oxime derivatives related to AP18: Agonists and antagonists of the TRPA1 receptor.

J. Defalco, Amy Gustafson, D. Emerling, 2010, Bioorganic & medicinal chemistry letters.

The discovery of an orally efficacious positive allosteric modulator of the calcium sensing receptor containing a dibenzylamine core.

S. Morony, J. Reagan, David A. Martin, 2010, Bioorganic & medicinal chemistry letters.

Melanocortin subtype-4 receptor agonists containing a piperazine core with substituted aryl sulfonamides.

N. Chen, C. Fotsch, A. Bannon, 2005, Bioorganic & medicinal chemistry letters.

2-Amino-5-arylbenzoxazole derivatives as potent inhibitors of fatty acid amide hydrolase (FAAH)

Fabien Vincent, D. Emerling, M. Duncton, 2012 .

Synthesis of Hexahydrocyclopentimidazol-2-(1H)-one derivatives displaying selective DP-receptor agonist properties.

A. Robertson, C. Harris, P. Leff, 1996, Bioorganic & medicinal chemistry.

The antagonism by BW A868C of PGD2 and BW245C activation of human platelet adenylate cyclase

A. Robertson, J. Wood, M. Kelly, 1989, British journal of pharmacology.

MCC/SNAr methodology. Part 1: Novel access to a range of heterocyclic cores

C. Hulme, P. Tempest, V. Ma, 2001 .

Short solution phase preparation of fused azepine-tetrazoles via a UDC (Ugi/de-Boc/cyclize) strategy

C. Hulme, Thomas E. Nixey, D. Semin, 2002 .

Preparation of heteroaryloxetanes and heteroarylazetidines by use of a Minisci reaction.

M. Cox, M. Duncton, M. A. Estiarte, 2009, The Journal of organic chemistry.

Two-step solution-phase synthesis of novel benzimidazoles utilizing a UDC (Ugi/de-Boc/cyclize) strategy

C. Hulme, P. Tempest, V. Ma, 2001 .

The one-pot solution phase preparation of fused tetrazole-ketopiperazines

C. Hulme, Thomas E. Nixey, M. Kelly, 2000 .

Highly convergent and efficient total synthesis of prostaglandins (.+-.)-PGA and (.+-.)-PGB

J. Marino, M. Kelly, 1981 .

Design of a new peptidomimetic agonist for the melanocortin receptors based on the solution structure of the peptide ligand, Ac-Nle-cyclo[Asp-Pro-DPhe-Arg-Trp-Lys]-NH(2).

Michael G Kelly, J. Cheetham, M. Jarosinski, 2003, Bioorganic & medicinal chemistry letters.

Preparation of aryloxetanes and arylazetidines by use of an alkyl-aryl suzuki coupling.

M. Cox, M. Duncton, M. A. Estiarte, 2008, Organic letters.

Dibutyl 2-(trifluoromethyl)cyclopropylboronate as a useful (trifluoromethyl)cyclopropyl donor: application to antagonists of TRPV1

M. Duncton, N. Orike, J. Kincaid, 2010 .

Reaction of isoprene and dimethyl acetylenedicarboxylate in the presence of cyclododeca-1,5,9-trienylnickel: formation of cyclotetradecatetraene derivatives and a novel rearrangement of an intermediate π-allyl-nickel complex under the influence of carbon monoxide

R. Baker, M. Kelly, 1980 .

The classification of prostaglandin DP‐receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist

A. Robertson, P. Leff, H. Giles, 1989, British journal of pharmacology.

Identification and characterization of novel TRPV4 modulators.

J. Defalco, Amy Gustafson, D. Emerling, 2009, Biochemical and biophysical research communications.

Development and Evaluation of an Enzyme Inhibition Assay for Methotrexate

M. Kelly, 1988, Annals of clinical biochemistry.

Synthesis and biological evaluation of benzodioxanylpiperazine derivatives as potent serotonin 5-HT(1A) antagonists: the discovery of Lecozotan.

B. Harrison, D. Huryn, W. Childers, 2005, Journal of medicinal chemistry.

Correlating Efficacy in Rodent Cognition Models with In Vivo 5-HT 1 A Receptor Occupancy by a Novel Antagonist

Hughes, M. Day, T. Comery, 2008 .

Correlating Efficacy in Rodent Cognition Models with in Vivo 5-Hydroxytryptamine1A Receptor Occupancy by a Novel Antagonist, (R)-N-(2-Methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane Carboxamide (WAY-101405)

M. Day, T. Comery, S. Grauer, 2008, Journal of Pharmacology and Experimental Therapeutics.

Cercosporin from Cercospora hayii

R. Mumma, F. Lukezic, M. Kelly, 1973 .

Activities of Lead Chloride in Molten PbCl2–KCl–NaCl and PbCl2–KCl–LiCl Ternary Systems

J. M. Toguri, M. Kelly, M. Hino, 1990 .

Discovery of potent, orally available vanilloid receptor-1 antagonists. Structure-activity relationship of N-aryl cinnamides.

N. Chen, J. Treanor, P. Chakrabarti, 2005, Journal of medicinal chemistry.

MCC/SNAr Methodology. Part 1. Novel Access to a Range of Heterocyclic Cores.

C. Hulme, P. Tempest, V. Ma, 2001 .

Identification of orally-bioavailable antagonists of the TRPV4 ion-channel.

J. Defalco, Qingling Zhang, Amy Gustafson, 2015, Bioorganic & medicinal chemistry letters.

Synthesis of novel melanocortin 4 receptor agonists and antagonists containing a succinamide core.

C. Fotsch, Markian M Stec, N. Xi, 2004, Bioorganic & medicinal chemistry letters.

Structure-activity relationship of (1-aryl-2-piperazinylethyl)piperazines: antagonists for the AGRP/melanocortin receptor binding.

J. Cheetham, K. Stark, C. Fotsch, 2003, Journal of medicinal chemistry.

Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.

D. Emerling, M. Duncton, M. Nguyen, 2009, Bioorganic & medicinal chemistry letters.

2-Amino-5-arylbenzoxazole derivatives as potent inhibitors of fatty acid amide hydrolase (FAAH)

D. Emerling, M. Duncton, D. J. R. O'mahony, 2012 .

Preparation of aryloxetanes and arylazetidines by use of an alkyl-aryl suzuki coupling.

M. Cox, M. Duncton, D. J. R. O'mahony, 2008, Organic letters.

Discovery of potent, non-carbonyl inhibitors of fatty acid amide hydrolase (FAAH)

J. Defalco, D. Emerling, M. Duncton, 2012 .